Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 413611-93-5 Chemical Structure| 413611-93-5

Structure of 10074-G5
CAS No.: 413611-93-5

Chemical Structure| 413611-93-5

10074-G5

CAS No.: 413611-93-5

10074-G5 is a c-Myc Max interaction inhibitor.

4.5 *For Research Use Only !

Cat. No.: A188479 Purity: 99%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łË˶ÊÊ Inquiry Inquiry
5mg łÍʶÊÊ Inquiry Inquiry
10mg łÿď¶ÊÊ Inquiry Inquiry
25mg łîò¶ÊÊ Inquiry Inquiry
50mg łÇͧ¶ÊÊ Inquiry Inquiry
100mg łËÇͶÊÊ Inquiry Inquiry
250mg łÍÊò¶ÊÊ Inquiry Inquiry
1g łÇÊÊî¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łË˶ÊÊ

  • 5mg

    łÍʶÊÊ

  • 10mg

    łÿď¶ÊÊ

  • 25mg

    łîò¶ÊÊ

  • 50mg

    łÇͧ¶ÊÊ

  • 100mg

    łËÇͶÊÊ

  • 250mg

    łÍÊò¶ÊÊ

  • 1g

    łÇÊÊî¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 10074-G5

CAS No. :413611-93-5
Formula : C18H12N4O3
M.W : 332.31
SMILES Code : O=[N+](C1=CC=C(NC2=CC=CC=C2C3=CC=CC=C3)C4=NON=C41)[O-]
MDL No. :MFCD00576774
InChI Key :KMJPYSQOCBYMCF-UHFFFAOYSA-N
Pubchem ID :2836600

Safety of 10074-G5

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H315-H319-H335
Precautionary Statements:P261-P301+P310-P305+P351+P338
Class:6.1
UN#:2811
Packing Group:

Related Pathways of 10074-G5

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Myc-Cap cells 25 μM 24 h Evaluate the effect of Myc inhibitors on GFAT1 expression and protein glycosylation. Results showed that 10074-G5 significantly upregulated GFAT1 expression and increased protein glycosylation levels. PMC9830436
RM1 cells 25 μM 24 h Evaluate the effect of Myc inhibitors on GFAT1 expression and protein glycosylation. Results showed that 10074-G5 significantly upregulated GFAT1 expression and increased protein glycosylation levels. PMC9830436
PC3 cells 25 μM 24 h Evaluate the effect of Myc inhibitors on GFAT1 expression and protein glycosylation. Results showed that 10074-G5 significantly upregulated GFAT1 expression and increased protein glycosylation levels. PMC9830436
Monomeric Aβ40 200 μM Measure heat changes upon 10074-G5 binding to Aβ40 using isothermal titration calorimetry, indicating the interaction is largely entropic PMC7673680
Monomeric Aβ42 20 μM Characterize the binding of 10074-G5 to monomeric Aβ42, finding Aβ42 remains disordered in the bound form PMC7673680
HL-60 human promyelocytic leukemic cells 13.5 ± 2.1 μM 72 h To evaluate the growth inhibitory potency of 10074-G5 against HL-60 cells, results showed that 10074-G5 effectively inhibited cell growth PMC2993546
Daudi Burkitt’s lymphoma cells 15.6 ± 1.5 μM 72 h To evaluate the growth inhibitory potency of 10074-G5 against Daudi cells, results showed that 10074-G5 effectively inhibited cell growth PMC2993546
Human renal proximal tubule cells (RPTCs) 30 μM 3 h Pre-treatment with 10074-G5 completely restored FEN-stimulated cAMP accumulation in uRPTCs to normal levels. PMC3640476
Human renal proximal tubule cells (RPTCs) 30 μM 24 h 10074-G5 completely blocked the PMA-mediated increase in GRK4 expression, restoring GRK4 expression to basal levels. PMC3640476
ALK+ALCL cells 5 μM 24 h Inhibits MYC-MAX heterodimerization and their DNA binding, significantly abrogating H2O2-induced RU/RR conversion PMC5879562

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice RM-1 prostate cancer model Intravenous injection 10 mg/kg Once every 3 days, total 5 times Evaluate the antitumor activity of 10074-DON-loaded PS nanocarrier in vivo. Results showed that PS/10074-DON significantly inhibited tumor growth and improved the tumor immune microenvironment. PMC9830436
Caenorhabditis elegans GMC101 strain Administered via culture medium 5 μM Continuous administration starting from L4 larval stage Evaluate the effect of 10074-G5 on Aβ42 aggregation-associated toxicity, showing 10074-G5 reduces amyloid load and improves behavioral parameters in worms PMC7673680
C.B-17 SCID mice Daudi Burkitt’s lymphoma xenografts Intravenously 20 mg/kg Once daily for 5 days To evaluate the antitumor efficacy of 10074-G5 in vivo, results showed that 10074-G5 did not significantly inhibit the growth of Daudi xenografts PMC2993546

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.01mL

0.60mL

0.30mL

15.05mL

3.01mL

1.50mL

30.09mL

6.02mL

3.01mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories